190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

K. Park; J. Y. Han; D. W. Kim; L. A. Bazhenova; S. H. Ou; Y. K. Pang; H. S. Hin; O. Juan; J. Son; P. Jänne

doi:10.1016/S1556-0864(16)30299-4

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

K. Park
, J. Y. Han
, D. W. Kim
, L. A. Bazhenova
, S. H. Ou
, Y. K. Pang
, H. S. Hin
, O. Juan
, J. Son
, P. Jänne

Department of Internal Medicine

National Cancer Center Korea
Seoul National University
University of California at San Diego
University of California at Irvine
University of Malaya
International Islamic University Malaysia
Hospital Universitario La Fe
Hanmi Pharmaceutical Co., Ltd.
Dana-Farber Cancer Institute

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Original language	English
Pages (from-to)	S139
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30299-4
State	Published - Apr 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1556-0864(16)30299-4

Cite this

Park, K., Han, J. Y., Kim, D. W., Bazhenova, L. A., Ou, S. H., Pang, Y. K., Hin, H. S., Juan, O., Son, J., & Jänne, P. (2016). 190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). Journal of Thoracic Oncology, 11(4), S139. https://doi.org/10.1016/S1556-0864(16)30299-4

@article{3071f59156d5404da0bb5d397829d6fa,

title = "190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)",

author = "K. Park and Han, \{J. Y.\} and Kim, \{D. W.\} and Bazhenova, \{L. A.\} and Ou, \{S. H.\} and Pang, \{Y. K.\} and Hin, \{H. S.\} and O. Juan and J. Son and P. J{\"a}nne",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30299-4",

language = "English",

volume = "11",

pages = "S139",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "4",

}

Park, K, Han, JY, Kim, DW, Bazhenova, LA, Ou, SH, Pang, YK, Hin, HS, Juan, O, Son, J & Jänne, P 2016, '190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)', Journal of Thoracic Oncology, vol. 11, no. 4, pp. S139. https://doi.org/10.1016/S1556-0864(16)30299-4

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). / Park, K.; Han, J. Y.; Kim, D. W. et al.
In: Journal of Thoracic Oncology, Vol. 11, No. 4, 04.2016, p. S139.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 190TiP

T2 - ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

AU - Park, K.

AU - Han, J. Y.

AU - Kim, D. W.

AU - Bazhenova, L. A.

AU - Ou, S. H.

AU - Pang, Y. K.

AU - Hin, H. S.

AU - Juan, O.

AU - Son, J.

AU - Jänne, P.

PY - 2016/4

Y1 - 2016/4

UR - https://www.scopus.com/pages/publications/84988949971

U2 - 10.1016/S1556-0864(16)30299-4

DO - 10.1016/S1556-0864(16)30299-4

M3 - Article

AN - SCOPUS:84988949971

SN - 1556-0864

VL - 11

SP - S139

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

UN SDGs

Access to Document

Other files and links

Cite this